Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Metastatic Osteosarcoma: early-phase trial registry

3 of 9 indexed Metastatic Osteosarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Metastatic Osteosarcoma: 9 US clinical trials tracked, 3 recruiting.

Metastatic Osteosarcoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition metastatic-osteosarcoma

OPEN 3 | RECR 33% | LATE 2 | EARLY 7 | RANK #1916 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Metastatic Osteosarcoma (thi…33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Metastatic Osteosarcoma

Metastatic Osteosarcoma lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Osteosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Osteosarcoma is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Metastatic Osteosarcoma research.

    M.D. Anderson Cancer Center accounts for 3 of 9 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Metastatic Osteosarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Metastatic Osteosarcoma research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 26Phase 32

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2 1,122 participants

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

NCT05691478

RECRUITING Phase 3 62 participants

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Children's Oncology Group

NCT05235165

RECRUITING Phase 2 40 participants

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

M.D. Anderson Cancer Center

NCT05019703

ACTIVE NOT RECRUITING Phase 2 75 participants

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

M.D. Anderson Cancer Center

NCT04668300

ACTIVE NOT RECRUITING Phase 1 70 participants

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

M.D. Anderson Cancer Center

NCT01590069

COMPLETED Phase 3 1,334 participants

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Children's Oncology Group

NCT00134030

COMPLETED Phase 2 178 participants

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Northwestern University

NCT02357810

COMPLETED Phase 2 41 participants

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

National Cancer Institute (NCI)

NCT02484443

COMPLETED Phase 2 20 participants

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Wake Forest University Health Sciences

NCT01553539

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 2

Named interventions

Most-linked intervention names on Metastatic Osteosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Doxorubicin Hydrochloride Drug
2 trials
Cisplatin Drug
2 trials
Computed Tomography Procedure
2 trials
Oral Topotecan Hydrochloride Drug
1 trials
therapeutic angiotensin-(1-7) Drug
1 trials
Aerosolized Aldesleukin Biological
1 trials
Dinutuximab Biological
1 trials

US sites by state

Facility locations filed on Metastatic Osteosarcoma trials. A trial with sites in several states counts in each.

Arizona 5 trials
California 4 trials
Arkansas 4 trials
Alabama 4 trials
Texas 3 trials
Florida 2 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Osteosarcoma page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Osteosarcoma condition card totals 9 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.